SCHEMBL4995145

SCHEMBL4995145

O=C(O)CCCc1ccc(NC=C2C(=O)Nc3ccccc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
MAPK1 P28482 2/20 0.48
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
TGM2 P21980 1/20 0.46
IDO1 P14902 1/20 0.46
KDR P35968 6/20 0.46
FGFR1 P11362 5/20 0.46
PDGFRB P09619 4/20 0.46
FLT1 P17948 3/20 0.46
AURKA O14965 3/20 0.46
RET P07949 2/20 0.46
FLT3 P36888 2/20 0.46
ZAP70 P43403 2/20 0.46
MAP4K2 Q12851 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995141 1.00 ALDH1A1 (0.48) ALDH1A1MAPTMAPK1KDM4EPKM
SCHEMBL4991358 0.93 KDR (0.50) ALDH1A1MAPTMAPK1KDM4EPKM
SCHEMBL4991346 0.93 KDR (0.50) ALDH1A1MAPTMAPK1KDM4EPKM
SCHEMBL6599118 0.90 FGFR1 (0.47) ALDH1A1MAPTMAPK1KDM4EPKM
SCHEMBL3566664 0.90 HDAC3 (0.46) ALDH1A1MAPTMAPK1KDM4ENPSR1
SCHEMBL3566661 0.90 HDAC3 (0.46) ALDH1A1MAPTMAPK1KDM4ENPSR1
SCHEMBL4991617 0.86 MAPT (0.52) ALDH1A1MAPTMAPK1KDM4EPKM
SCHEMBL4991606 0.86 MAPT (0.52) ALDH1A1MAPTMAPK1KDM4EPKM
SCHEMBL4994228 0.86 IDO1 (0.52) TGM2IDO1PDGFRBZAP70
SCHEMBL4994235 0.86 IDO1 (0.52) TGM2IDO1PDGFRBZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 ALDH1A1 1651/4885MAPT 3370/4885MAPK1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.